Advanced search
Publication Cover
Leukemia & Lymphoma Volume 43, 2002 - Issue 1
Submit an article Journal homepage
108
Views
50
CrossRef citations to date
0
Altmetric
Research Article

Treatment of Refractory Peripheral T-cell Lymphoma with Denileukin Diftitox (ONTAK ® )

Rakhshandra Talpur Division of Internal Medical Specialties, Department of Dermatology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030-4095, USA
,
Narin Apisarnthanarax Division of Internal Medical Specialties, Department of Dermatology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030-4095, USA
,
Staci Ward Division of Internal Medical Specialties, Department of Dermatology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030-4095, USA
&
Madeleine Duvic Division of Internal Medical Specialties, Department of Dermatology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030-4095, USA
Pages 121-126 | Published online: 01 Jul 2009

  • Jaffe, E.S. (1984) "Pathologic and clinical spectrum of post-thymic T-cell malignancies", Cancer Investigation 2,413-426.
  • Lennert, K. and Feller. A.C, (1992) Histopathology of Non-Hodgkin's Lymphomas (Springer, Berlin), pp 165-260.
  • Lopez-Guillermo, A., Cid J., Salar, A., et al. (1998) "Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. classification", Annals of Oncology 9(8), 849- 855.
  • Campo, E., Gaulard. P., Zucca, E. et al. (1998) "Report of the European task force on lymphomas: workshop on peripheral T-cell lymphomas", Annals of Oncology 9, 835-843.
  • Ko, Y.H. and Lee, J.D. (1991) "Peripheral T-cell lymphoma clinicopathologic and immunophenotypic analysis of 25 cases", Journal of Korean Medical Science 6(4), 329-337.
  • Carbone, P.T. et al. (1971) "Symposium (Ann Arbor): staging of Hodgkin's disease", Cancer Research 31, 1707-1860.
  • Haioum, C., Gaulard. P., Bourquelot, P. et al. (1992) "Clinical and biological analysis of peripheral T-cell lymphoma: a single institution study", Leukemia and Lymphoma 7(5-6), 449-455.
  • Jacobs, P. (2000) "Lymphoma-histopathology in changing clinical prospective. Non-Hodgkin's, lymphoma classification project", South African Medical Journal 90(2), 135-141.
  • Ontak (denileukm diftitox) product monograph (1999) Ligand Pharmaceuticals.
  • Kuzel, T.M., Olsen, E., Mann, A. et al. (1997) "Pivotal phase III trial of DAB-II. 2 (ONTAK*) as the treatment of mycosis fungoides", Blood 90(1), 586a.
  • Wasik, M.A., Vonderheid, E.C., Bigler, R.D. et al. (1996) "Increased serum concentration of soluble interleukin-2 receptor in cutaneous T-cell lymphoma", Archives of Dermatology 132, 42-47.
  • Hoppe, R.T., Meideiros, L.J., Warnke, R.A. et al. (1995) "CD8+ tumor-infiltrating lymphocytes influence survival of patients with mycosis fungoides", Journal of American Academy of Dermatology 32,448-453.
  • Talpur, R. and Duvic, M. (2000) "Treatment of mycosis fungoides with Denileukin diftitox", Case studies in Oncology 2(7).
  • Kurzrock, R., Pilat, S. and Duvic, M. (1999) "Pentostatin therapy of T-cell lymphomas with cutaneous manifestation", Journal of Clinical Oncology 17(10), 3117-3121.
  • Zinzani, P.L. (2000) "Gemcitabine treatment is pretreated cutaneous T-cell lymphoma: experience in 44 patients", Journal of Clinical Oncology 18(13), 2603-2606.
  • Zaja, F., Rusoo, D., Silvestri, F. et al. (1997) "Retrospective analysis of 23 cases with peripheral T-cell lymphoma, unspecified: clinical characteristics and outcome", Haematologica 82(2), 171 -177.
  • Vonderheid, E.C., Zhand, Q., Lessin, S.R. et al. (1998) "Use of serum soluble intcrlukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma", Journal of American Academy of Dermatology 38(2), 207-220.
  • LeMaistre, C.F., Saleh, M.N., Kuzel, T.M. et al. (1998) "Phase I Trail of a ligand fusion protein (DAB389 IL-2) in lymphomas expressing the receptor for Interleukin-2", Blood 91, 399 -405.
  • Olsen, E. A., Duvic, M., Martin, A. et al. (2001) "Pivotal phase III trial of two dose levels of DAB389 IL-2 (ONTAK*) for the treatment of cutaneous T-cell lymphoma (CTCL.)", Journal of Clinical Oncology 19(2), 376-388.
  • Coiffier, B., Duvic, M. and Link, B. K. (1999) "Current status of fusion protein DAB 389-IL-2 (denileukin diftitox) in the management of cutaneous T-cell lymphoma", Biological therapies of lymphoma, 7-9.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.